Operates a multi-specialty hospital chain across several Indian states including Telangana, Andhra Pradesh, Karnataka, Maharashtra, and Kerala. Revenue is generated from inpatient and outpatient hospital services, with Q4 FY26 inpatient volumes up 17.9% YoY and outpatient volumes up 30.1% YoY. The company expanded into 8 new locations in FY26 — Kompally, Guntur (two facilities), Thane, Sangli, Bangalore Mahadevapura and Electronic City, Kerala Kollam, plus a mother-and-child unit at Nellore — and is consolidating the 300-bed Palakkad acquisition. Mature hospitals run at ~29.5% EBITDA margin, while overall FY26 EBITDA margin was 20.9% as newly commissioned units dragged INR 128 crore on EBITDA. Employee costs of 17.5% of revenue are the largest disclosed cost line, with capex at 36.6% of revenue reflecting the build-out. A INR 1,500 crore QIP closed in June 2026 is being used to retire ~INR 1,000 crore of debt and target net debt/EBITDA of ~2x against ~3.5x currently. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Inpatient hospital services, Outpatient hospital services. Asset-heavy multi-specialty hospital chain in an aggressive expansion phase, with mature units at ~29.5% EBITDA margin offset by new-unit drag
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 1,651 | 2,198 | 2,498 | 3,035 | 3,905 |
| EBITDA (ex other income) | 516 | 619 | 640 | 794 | 791 |
| margin % | 31.2 | 28.2 | 25.6 | 26.2 | 20.3 |
| Owners' profit | 333 | 336 | 310 | 385 | 241 |
| EPS, as reported (₹) | 41.88 | 42.03 | 38.75 | 9.61 | 6.03 |
| ROE % · ROCE % | 24.4 · 27.4 | 18.9 · 19.5 | 16.1 · 14.9 | 17.1 · 13.2 | 9.5 · 8.2 |
| Debt / equity (x) | 0.11 | 0.35 | 0.65 | 1.06 | 1.27 |
| Cash from operations | 520 | 432 | 521 | 582 | 511 |
| Capex | (170) | (526) | (647) | (1,009) | (1,428) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 777 | 772 | 797 | 872 | 961 | 998 | 1,075 | 1,180 |
| Profit before tax | 162 | 135 | 134 | 114 | 97 | 69 | 52 | 56 |
| Net profit | 121 | 93 | 106 | 85 | 72 | 52 | 33 | 37 |
| EPS (₹) | 2.68 | 2.22 | 2.54 | 1.96 | 1.67 | 1.33 | 1.06 | 1.04 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| APOLLO HOSPITALS ENTER. L | 1,27,062 | 60.8 | 12.74 | 33.5 | 20.1 | 16.6 | 19.0 | 16.2 |
| MAX HEALTHCARE INS LTD | 1,00,993 | 69.2 | 9.40 | 44.0 | 13.4 | 11.1 | 27.3 | 27.0 |
| FORTIS HEALTHCARE LTD | 67,025 | 64.0 | 6.59 | 32.9 | 10.5 | 9.7 | 17.8 | 22.0 |
| ASTER DM QUALITY CARE LTD | 39,689 | 124.0 | 8.21 | 40.4 | 8.8 | 8.5 | (11.6) |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 10 Sept 2026 · KIMS signs O and M deal to manage 183 bed hospital in Kakinada | strategic transactions | medium | — | — |
| 7 Sept 2026 · KIMS to meet institutional investors on Sept 10 hosted by Emkay | board shareholder meetings | low | — | — |
| 30 Aug 2026 · KIMS 24th AGM: all 5 resolutions passed, notable institutional dissent on some | board shareholder meetings | low | — | — |
| 27 Aug 2026 · 24th AGM held; 5 resolutions tabled including director re-appointment | board shareholder meetings | low | — | — |
| 26 Aug 2026 · KIMS denies reports of Renova Hospitals stake acquisition talks | strategic transactions | medium | — | — |
| 20 Aug 2026 · KIMS signs O&M deal for 250-bed Arete Hospitals in Hyderabad | strategic transactions | high | — | — |
| 19 Aug 2026 · KIMS allots 77 lakh warrants to promoters at Rs 779 each | fund raising | high | — | — |
| 8 Aug 2026 · KIMS Hospitals Q1 FY27 earnings call transcript filed | investor communications | medium | — | — |
| 7 Aug 2026 · KIMS gets NSE/BSE nod for 77 lakh warrants to promoters | fund raising | high | — | — |
| 7 Aug 2026 · KIMS gets in-principle nod for 77 lakh warrants to promoters | fund raising | high | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| 14.3 |
| GLOBAL HEALTH LIMITED | 38,972 | 70.0 | 9.78 | 39.4 | 13.9 | 13.5 | — | 23.7 |
| NARAYANA HRUDAYALAYA LTD. | 38,213 | 46.5 | 8.42 | 25.4 | 17.8 | 9.2 | 25.0 | 18.8 |
| KRISHNA INST OF MED SCI L ◆ | 32,235 | 150.5 | 12.60 | 43.4 | 9.5 | 5.1 | 24.0 | 20.3 |
| DR AGARWALS HEALTH CARE L | 16,043 | 107.9 | 7.57 | 26.2 | 7.9 | 7.1 | — | 28.8 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 150.5 | 47.3 | 28 of 30 | 7% |
| P/B | 12.6 | 6.2 | 23 of 24 | 4% |
| ROCE | 5.1 | 10.9 | 23 of 30 | 24% |
| ROE | 9.5 | 11.8 | 16 of 24 | 35% |
| Debt / Equity | 1.3 | 0.2 | 24 of 24 | 0% |
| EBITDA margin | 20.3 | 22.0 | 17 of 24 | 30% |
| Revenue growth | 35.3 | 20.2 | 3 of 23 | 91% |
| Profit growth | (56.0) | 8.1 | 19 of 21 | 10% |
| Market cap | 32235 | 2415 | 7 of 30 | 79% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
